

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,937	01/24/2005	Gregory Alan Steube	S-8494 (1502-88 PCT US)	2176
	7590 03/12/200 UCA, FARRELL & S	EXAMINER		
	OLLOW ROAD	berman, susan w		
MELVILLE, NY 11704			ART UNIT	PAPER NUMBER
			1711	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS 03/12/2007 PAPER		FR		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Application No. Applicant(s) In/621,337 STEUBE, GREGORY ALAN					L-				
Examiner Susan W. Berman - The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Repty - The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Repty - A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - AN Operiod for reply is specified some, the maximum databout period will apply and will apple SK (MONTHS from the mailing date of this communication. - AN Operiod for reply is specified some, the maximum databout period will apply and will apple SK (MONTHS from the mailing date of this communication. - AN Operiod for reply is specified some, the maximum databout period will apply and will apply sk (MONTHS from the mailing date of this communication. - AN Operiod for reply is specified some, the maximum databout period will apply and will apply sk (MONTHS from the mailing date of this communication. - AN Operiod for reply is specified some, the maximum databout period will apply and will apply sk (MONTHS from the mailing date of this communication. - AN Operiod for reply is specified and the maximum databout period will apply and will apply she will be supply and will apply sk (MONTHS from the mailing date of this communication. - AN Operiod for the specification is communication. - AN Operiod for the apply calculation is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Exparte Quayle, 1935 C.D. 11, 453 O.G. 213. - Disposition of Claims - Application of Claims - Application of Claims - Application of Claims - Application Papers - Signal of the above claim(s) islare allowed. - Cla			Application No.	Applicant(s)	·				
Susan W. Berman 1711			10/521,937	STEUBE, GREGORY ALA	AN				
- The MALING DATE of this communication appears on the cover sheet with the correspondence address — Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 2 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensive of internety be available under the provided use of 27 CR1 13(6), hin to event, nower, may a reply be trively filled If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failute to reply within the set or extended period for right will be placed for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failute to reply within the set or extended period for right will, by statuse, cause the application C year. It is secured patient term adjustment. Set 37 CFR 17/40(7) Responsive to communication(s) filled on			Examiner	Art Unit					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHITCHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. ASHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHITCHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Belieshord from raply be switched under the processor of the communication of the processor of the proc									
WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Exercision of time may be available under the provision of 3° CFR 1.18(a). In no event, however, may a reply be timely filed and 100 (b) MONTHS from the mailing date of this communication. **Failunt or reply which his east or excented paried for reply will, by statios, used the segment of the become ABANDONEO 30 u.S. C. § 133). **Any reply received by the Office later than three months affor the mailing date of this communication, even if timely filed, may reduce any seamed patient them adjustment. See 3° CFR 1.70(b). **Status** 1) □ Responsive to communication (s) filed on	Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the o	orrespondence address					
1)	WHIC - Exte after - If NC - Failu Any	CHEVER IS LONGER, FROM THE MAILING DA nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. o period for reply is specified above, the maximum statutory period we re to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communicati D (35 U.S.C. \$ 133)					
2a) ☐ This action is FINAL. 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) ☐ Claim(s)22 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are objected to. 7) ☐ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on _24 January 2005 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. 5) ☐ Notice of Informal Patent Application	Status	•							
2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s)22 is/are pending in the application.	1)	Responsive to communication(s) filed on		•					
3	_								
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4)	· —	_							
4) □ Claim(s) 1-22 is/are pending in the application. 4a) Of the above claim(s)									
4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are objected to. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on 24 January 2005 is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	Dispositi	on of Claims							
4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are objected to. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on 24 January 2005 is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority documents have been received. 2. □ Certified copies of the priority documents have been received in Application No 3. □ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.	4)🖂	Claim(s) 1-22 is/are pending in the application.	•	•					
5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on 24									
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on _24 January 2005 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All _b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of Partsperson's Patent Drawing Review (PTO-948) 2) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application		_							
Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on 24 January 2005 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) Attachment(s) Attachment(s) Attachment(s) Disclosure Statement(s) (PTO-892) Attachmenton Disclosure Statement(s) (PTO-898)	6)⊠								
Application Papers 9) ☐ The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on 24 January 2005 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) ☐ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☐ Information Disclosure Statement(s) (PTO/SB/08) 5) ☐ Notice of Informal Patent Application	7)	Claim(s) is/are objected to.	•						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on 24 January 2005 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some colonic None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application	8)[Claim(s) are subject to restriction and/or	r election requirement.						
10) ☐ The drawing(s) filed on 24 January 2005 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No. ☐	Applicati	on Papers							
10) ☐ The drawing(s) filed on 24 January 2005 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No. ☐	9) 又	The specification is objected to by the Examine							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) (1) Notice of References Cited (PTO-892) (2) Notice of Draftsperson's Patent Drawing Review (PTO-948) (3) Information Disclosure Statement(s) (PTO/SB/08) 1 Notice of Informal Patent Application		· · · · · · · · · · · · · · · · · · ·		to by the Examiner.					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Informal Patent Application	<i>,</i> —.								
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) ☑ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☑ Notice of Informal Patent Application				, ,	(d).				
12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) Attachment(s) Attachment(s) Attachment(s) A Description of Disclosure Statement(s) (PTO-892) A Description of Disclosure Statement(s) (PTO-948) A Description of Disclosure Statement(s) (PTO/SB/08) A Description of Disclosure Statement(s) (PTO/SB/08) A Description of Disclosure Statement(s) (PTO/SB/08)	11)				(-)				
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) Notice of References Cited (PTO-892)	Priority ι	inder 35 U.S.C. § 119							
2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. *Attachment(s) 1) ☑ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☑ Information Disclosure Statement(s) (PTO/SB/08) * Information Disclosure Statement(s) (PTO/SB/08) * Information Disclosure Statement(s) (PTO/SB/08)		☐ All b)☐ Some * c)☐ None of:)-(d) or (f).					
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. *Attachment(s) 1) ☑ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☑ Information Disclosure Statement(s) (PTO/SB/08) * See the attached detailed Office action for a list of the certified copies not received. 4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date Paper No(s)/Mail Date 5) ☐ Notice of Informal Patent Application				•					
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) Notice of References Cited (PTO-892)									
* See the attached detailed Office action for a list of the certified copies not received. *Attachment(s) Attachment(s)				ed in this National Stage					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application	+ 6								
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application		see the attached detailed Office action for a list	of the certified copies not receive	;d.					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date 5) Notice of Informal Patent Application									
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date Notice of Informal Patent Application		• •							
B) Notice of Informal Patent Application) Motice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Page 18 (2) (Mail Date								
		3) 🔯 Information Disclosure Statement(s) (PTO/SB/08) 5) 🛄 Notice of Informal Patent Application							

Specification

The disclosure is objected to because of the following informalities: the disclosure on page 8 states that various silanes and silicone chloride are "polydimethylsiloxanes". However, none of these silanes is a polysiloxane, which, by definition, contains –(Si-O-Si-O-Si-O)_n- kinds of linkages. Thus the disclosure does not make it clear whether applicant is disclosing the silanes as the secondary silicone component or polydimethylsiloxanes having organo-functional groups obtained by polymerizing the silanes disclosed to obtain a polysiloxane as the secondary silicone component.

Appropriate correction is required.

Claim Objections

Claims 5, 13 and 19 are objected to because of the following informalities: The recitation "diaryliodonium, tetrakis(pentafluorophenyl)borate salt" should read "diaryliodonium tetrakis(pentafluorophenyl)borate salt". Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is not clear what kind of "silicone-epoxy copolymer" is intended to be claimed. Does applicant intend to claim a copolymer of a silicone monomer and an epoxy monomer? Does applicant intend to claim a silicone copolymer having epoxy pendant or end functional groups?

It is not clear how the "secondary silicone component" differs from the "silicone-epoxy copolymer". The second silicone is not clearly differentiated from the silicone-epoxy because it could also be a silicone epoxy of a different structure.

In claim 1, it is not clear whether applicant intends to claim a lubricant that is a <u>cured</u> product of the components set forth in claim 1 or to claim a composition comprising the components for providing a lubricant for medical devices. The claim should clearly recite either a cured product that is a lubricant for medical devices or a curable composition for providing a lubricant for medical devices when cured.

In claim 3, 11 and 17, the kinds of vinyl ethers being claimed are not clearly set forth. What is meant by a "monovinyl ether of 2-ethyl-1-1-hexanol, monovinyl ether"? Is this compound a monovinyl ether of a different monovinyl ether? What is the structure? It is suggested that the next recitations should read "divinyl ether of n-dodecanol", "divinyl ether of 1,4-cyclohexanedimethanol". It is not clear what the structure of ")H-stopped poly(tetrahydrofuran" is. Specifically, where are the vinyl ether groups in this vinyl ether and what does ")H" denote?

In claims 6, 14, 21 and 22, it is not clear what materials are encompassed by "silicone chloride". It is not clear what the structure of "vinyl trimethoryl silane" is. What is a 'methoryl" group? Does applicant intend "methoxy"? What structure is intended by "organosilane ester tri(3-(trimethoxysilyl)propyl)isocyanurate? It is suggested that applicant intends to recite tri(3-(trimethoxysilyl)propyl)isocyanurate, which is the name of the organosilane ester of isocynaurate.

In claim 7, Does applicant intend to set forth a property of the copolymer (or the composition comprising the copolymer?)? If so, the claim should recite "copolymer is <u>curable</u> by". Does applicant intend to set forth a lubricant that is a <u>cured product</u> of the composition set forth in claim 1? Is only the copolymer cured by exposure to radiation?

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5 and 7 are rejected under 35 U.S.C. 102(b) as being anticipated by Leir et al (5,576,356). Leir et al disclose cationically co-curable polysiloxane release compositions comprising an epoxy-functional polysiloxane (a) and a co-reactive monomer (b) with an cationic photocatalyst. Vinyl ether reactive diluents including species in instant claim 3 are taught in column 7, lines 25-27 and column 11. Iodonium salts including species in instant claim 5 are taught in column 7, lines 60-66. Coating and radiation curing is taught in column 8, lines 50-64. Examples 31 and 32 teach mixtures of epoxy silicone with mercapto-functional silicone, vinyl ethers and iodonium salt. Leir et al teach that the compositions provide release coatings so they would be expected to provide a lubricant for medical devices.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Leir et al (5,576,356), as applied to claims 1-5 and 7 above, further in view of Bilodeau (6,486,267). Leir et al do not teach adding another silicone component. Bilodeau teaches release compositions wherein the compound (A) can be a epoxy silicone and B is a curable organopolysiloxane, such as polydimethylsiloxane (column 3, line 26, to column 4, line 13).

It would have been obvious to one skilled in the art at the time of the invention to substitute the mixture of an organopolysiloxane and an epoxy silicone taught by Bilodeau for the siloxane having epoxy functionality in the analogous radiation curable compositions disclosed by Leir et al. One of ordinary skill in the art at the time of the invention would have been motivated by a reasonable expectation of providing useful coating compositions having release properties, as taught by Leir et al and by Bilodeau, in the absence of evidence to the contrary.

Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Leir et al (5,576,356), as applied to claims 1-5 and 7 above, further in view of Shepard et al (5,260,348). Leir et al do not teach adding another silicone component. Shepard et al disclose compositions comprising a silanol chain-stopped polydiorganisiloxane, an acyloxy, alkoxy or aryloxy-functional crosslinking agent and an onium salt. Iodonium salts are disclosed in column 4, lines 5-11. Crosslinking silanes are taught in column 3, lines 17-40. Polydiorganisiloxane plasticizers are taught in column 5, lines 24-62. Silane adhesion promoters, including alkoxysilanes and bis-1,3- trimethoxysilylpropyl- isocyanurate are taught (column 6, line 50, to column 7, line 25).

It would have been obvious to one skilled in the art at the time of the invention to include an additional organopolysiloxane or adhesion promoting silane taught by Shepard et al in the

analogous radiation curable compositions disclosed by Leir et al. One of ordinary skill in the art at the time of the invention would have been motivated by a reasonable expectation of providing useful coating compositions having release properties, as taught by Leir et al, in the absence of evidence to the contrary.

Allowable Subject Matter

Claims 8 and 16 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action.

Claims 9-15 and 17-22 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter:

Spielvogel et al (4,720,521) is the closest prior art known to the examiner. Spielvogel et al disclose silicone compositions having lubricating properties for coating hypodermic needles. Three reactive silicones comprising vinyl-functionality and hydrogen functionality form a crosslinked matrix for a non-reactive silicone that provides lubricity. Spielvogel et al teach that polydimethylsiloxane is a well known silicone lubricant (column 1, lines 52-63).

Epoxysilicones are not mentioned. The examiner has not noted any motivation to substitute the compositions taught by Leir et al for those disclosed by Spielvogel et al.

Applicant disclose in the "Background of the Invention" that coatings comprising polydimethylsiloxane and moisture curable amino-functional silicone dispersions are known in the art for coating hypodermic needles.

Conclusion

The following references are cited as art of interest.

Kline (6,022,050) discloses silicone release coating compositions. The compositions comprise an epoxy functional silicone, a reactive solvent, a reactive diluent, such as a vinylether, a wax-treated silica powder and a photoinitiator. Vinyl ether reactive diluents, such as divinyl ether of 1,4-cyclohexane dimethanol, and onium salts, such as bis(4-dodecylphenyl) iodonium salts, are taught in column 5, lines 54-67, and column 7, line 30, to column 8, line 31. Kline does not specifically teach adding a second silicone, but does teach adding flow agents, surface active agents or extending oils, among others (column 8, lines 53-60). Kline teaches applying the compositions to a substrate and UV curing (column 9, lines 49-64).

Eckberg et al (5,650,453) disclose UV curable compositions comprising blends of epoxysilicone polymer, vinyl ether monomer or oligomers and an iodonium photocatalyst.

Eckberg et al teach coating cellulosic or plastic film substrates and UV curing (column 5, lines 20-28). Eckberg et al do not teach adding a second silicone component.

Shipp, Jr. (6,787,490, filed 12-26-2001) discloses a lubricating donning agent compositions comprising mixtures of reactive and non-reactive silicones, such as polydimethylsiloxane and a polyether epoxy silicone (column 8, lines 4-14). Shipp, Jr. does not suggest compositions comprising a vinyl ether compound or a photoinitiator.

Greene (6,344,520) discloses addition crosslinkable epoxy-functional organopolysiloxane compositions comprising an aminosilane hardener. See column 7, lines 6-53, and the Examples. Greene teaches that the preferred aminosilanes provide coatings having superior weatherability

Application/Control Number: 10/521,937

Art Unit: 1711

Page 8

in terms of color and gloss retention. Addition of silicone flow agents is taught in column 8, lines

3-5. Photoinitiators and radiation curing are not mentioned.

Neither EP 1 004 612 nor EP 1 083 205, cited in the international Search Report,

discloses epoxy silicone compositions.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Susan W. Berman whose telephone number is 571 272 1067.

The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Seidleck can be reached on 571 272 1078. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

SB

3/3/07

Susan W Berman

Susax Berma

Primary Examiner

Art Unit 1711